TRCT
RCPI

Tower Research Capital (TRC)’s ROCK CREEK PHARMACEUTICALS INC COM STK (DE) RCPI Stock Holding History

Tower Research Capital (TRC)’s Portfolio RCPI Stock Details RCPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-18,116
Closed -$15K – 5680
2015
Q3 		$15K Sell
18,116
-285
-2% -$317 ﹤0.01% 2007
2015
Q2 		$28K Buy
+18,401
New +$43.8K ﹤0.01% 1830
2014
Q4 		– Sell
-383
Closed -$3K – 5381
2014
Q3 		$3K Sell
383
-662
-63% -$6.54K ﹤0.01% 3724
2014
Q2 		$15K Buy
+1,045
New +$18.1K ﹤0.01% 2073

Other funds holding RCPI

Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
KCM
Kempner Capital Management Galveston, Texas $106M AUM 29.1% 1-Year Est. Return
WP
WealthPLAN Partners Omaha, Nebraska $523M AUM 23.92% 1-Year Est. Return
IWMPD
Integrated Wealth Management (Palm Desert) Palm Desert, California $299M AUM 12.86% 1-Year Est. Return

Tower Research Capital (TRC)'s RCPI Position: Q4 2015 in Review

Tower Research Capital (TRC) sold out of ROCK CREEK PHARMACEUTICALS INC COM STK (DE) (RCPI) in Q4 2015, closing a stake of 18,116 shares — an estimated $15K sold.

Tower Research Capital (TRC) first reported a position in RCPI in Q2 2014 and held it in 4 quarters. The position peaked at $28K in Q2 2015. 9 funds tracked by Wall St. Rank hold RCPI as of Q4 2015.

  • Tower Research Capital (TRC) reported no remaining ROCK CREEK PHARMACEUTICALS INC COM STK (DE) position as of Q4 2015 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 18,116 ROCK CREEK PHARMACEUTICALS INC COM STK (DE) shares in Q4 2015, an estimated $15K.
  • Tower Research Capital (TRC) first reported a position in ROCK CREEK PHARMACEUTICALS INC COM STK (DE) in Q2 2014 and held it in 4 quarters.
  • Tower Research Capital (TRC)'s ROCK CREEK PHARMACEUTICALS INC COM STK (DE) position peaked at $28K in Q2 2015.
  • 9 funds tracked by Wall St. Rank held ROCK CREEK PHARMACEUTICALS INC COM STK (DE) as of Q4 2015.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2015, filed 10 Feb 2016.